MTEM Molecular Templates Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MTEM

Price (delayed)

$1.725

Market cap

$9.27M

P/E Ratio

0.96

Dividend/share

N/A

EPS

$1.8

Enterprise value

$7.49M

Molecular Templates is a clinical-stage company focused on the discovery and development of targeted biologic therapeutics. Its proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the ...

Highlights
The company's revenue has surged by 190% YoY and by 8% QoQ
MTEM's gross profit has surged by 190% year-on-year and by 8% since the previous quarter
MTEM's equity has soared by 128% YoY but it is down by 38% from the previous quarter
The EPS has dropped by 93% year-on-year and by 73% since the previous quarter
Molecular Templates's quick ratio has decreased by 36% YoY and by 7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://mtem.com
Peers: OMER OMGA

Key stats

What are the main financial stats of MTEM
Market
Shares outstanding
5.37M
Market cap
$9.27M
Enterprise value
$7.49M
Valuations
Price to earnings (P/E)
0.96
Price to book (P/B)
2.2
Price to sales (P/S)
0.14
EV/EBIT
N/A
EV/EBITDA
6.43
EV/Sales
0.13
Earnings
Revenue
$57.31M
EBIT
-$5.48M
EBITDA
$1.16M
Free cash flow
-$41.76M
Per share
EPS
$1.8
Free cash flow per share
-$9.28
Book value per share
$0.78
Revenue per share
$12.73
TBVPS
$7.86
Balance sheet
Total assets
$35.38M
Total liabilities
$31.17M
Debt
$9.74M
Equity
$4.21M
Working capital
-$549,000
Liquidity
Debt to equity
2.31
Current ratio
0.97
Quick ratio
0.68
Net debt/EBITDA
-1.53
Margins
EBITDA margin
2%
Gross margin
100%
Net margin
-14.2%
Operating margin
-19.1%
Efficiency
Return on assets
-16.8%
Return on equity
-7,646.1%
Return on invested capital
-20.7%
Return on capital employed
-30.3%
Return on sales
-9.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MTEM stock price

How has the Molecular Templates stock price performed over time
Intraday
4.55%
1 week
7.81%
1 month
-9.21%
1 year
-70.88%
YTD
-53.75%
QTD
-22.99%

Financial performance

How have Molecular Templates's revenue and profit performed over time
Revenue
$57.31M
Gross profit
$57.31M
Operating income
-$10.94M
Net income
-$8.12M
Gross margin
100%
Net margin
-14.2%
The company's revenue has surged by 190% YoY and by 8% QoQ
MTEM's gross profit has surged by 190% year-on-year and by 8% since the previous quarter
The net margin has soared by 97% YoY and by 71% from the previous quarter
MTEM's operating margin has surged by 96% year-on-year and by 62% since the previous quarter

Growth

What is Molecular Templates's growth rate over time

Valuation

What is Molecular Templates stock price valuation
P/E
0.96
P/B
2.2
P/S
0.14
EV/EBIT
N/A
EV/EBITDA
6.43
EV/Sales
0.13
The EPS has dropped by 93% year-on-year and by 73% since the previous quarter
MTEM's price to earnings (P/E) is 13% lower than its last 4 quarters average of 1.1
MTEM's equity has soared by 128% YoY but it is down by 38% from the previous quarter
MTEM's P/B is 61% below its 5-year quarterly average of 5.7
The company's revenue has surged by 190% YoY and by 8% QoQ
The price to sales (P/S) is 99% lower than the 5-year quarterly average of 12.8 and 72% lower than the last 4 quarters average of 0.5

Efficiency

How efficient is Molecular Templates business performance
The return on sales has surged by 98% year-on-year and by 77% since the previous quarter
Molecular Templates's return on invested capital has surged by 76% YoY and by 66% QoQ
Molecular Templates's ROA has soared by 76% YoY and by 59% from the previous quarter

Dividends

What is MTEM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MTEM.

Financial health

How did Molecular Templates financials performed over time
Molecular Templates's total assets is 14% more than its total liabilities
MTEM's total liabilities has dropped by 72% year-on-year and by 16% since the previous quarter
Molecular Templates's total assets has plunged by 64% YoY and by 20% from the previous quarter
The debt is 131% more than the equity
MTEM's debt to equity has soared by 172% year-on-year and by 51% since the previous quarter
MTEM's equity has soared by 128% YoY but it is down by 38% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.